Latest Regulatory News

Theta Gold Mines Limited has had its trading suspension lifted immediately following the release of a funding transaction announcement, signaling renewed market activity for the gold miner.

Theta Gold Mines Limited has locked in a substantial A$51.4 million funding package combining debt and equity to advance construction of its TGME Gold Project in South Africa. This milestone funding sets the stage for the company’s next phase despite recent revisions to its production forecasts.

360 Capital Mortgage REIT has announced an unfranked ordinary dividend of AUD 0.055 per unit for the September quarter, alongside the adoption of the Attribution Managed Investment Trust (AMIT) tax regime.

Halo Technologies has appointed Peter Oxlade as CEO and George Paxton as COO, aligning leadership with its recent $3.9 million capital raise to fuel expansion across the Asia-Pacific region.

St Barbara Limited has secured approximately A$58 million through an institutional placement to fund its Simberi Expansion Project and advance the 15-Mile Processing Hub in Nova Scotia. This capital raise supports the company’s growth ambitions amid ongoing regulatory and operational developments.

ECS Botanics reports a positive cash flow milestone in Q1 FY26, driven by strong direct-to-consumer sales and operational efficiencies, while preparing for a European market debut.

Koba Resources has acquired exclusive rights to two high-grade tin-tungsten projects in Queensland’s historic Herberton Tin Field, backed by a $4.35 million placement to fund exploration and drilling.

Koba Resources has acquired exclusive rights to two prolific tin-tungsten projects in Queensland’s historic Herberton Tin Field, backed by a $4.35 million capital raise to fund exploration and drilling.

EV Resources has entered a binding agreement to sell its Khartoum Project to Koba Resources for $700,000 cash plus a royalty, marking a strategic pivot towards its antimony assets and US critical minerals ambitions.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.

Mesoblast Limited reports a robust 66% increase in Ryoncil revenues for Q2 2025, driven by strong market adoption and new Medicare reimbursement codes.

Seafarms Group Limited has resumed trading on the ASX following the lifting of its suspension, triggered by the lodgement of its annual financial report.